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Background
Retroviruses are able to establish persistent infection
despite induction of a multipartite antiviral immune
response. Whether collective failure of all parts of the
immune response or selective deficiency in one crucial
part underlies the inability of the host to resist retroviral
infection is currently unclear.
Methods
Here we examine the contribution of the virus-specific
CD4+ T cells in protection against Friend virus (FV) infec-
tion in the murine host. We have developed a TCR-β
transgenic mouse with a polyclonal repertoire of CD4+ T
cells, which we adoptively transfer into a variety of differ-
ent hosts, with distinct genetic susceptibility or lym-
phocyte composition.
Results
We show that the magnitude and duration of the FV-spe-
cific CD4+ T cell response is directly proportional to resist-
ance against acute FV infection and subsequent disease,
demonstrating a previously unappreciated protective role.
Notably, significant protection against FV-induced disease
is afforded by FV-specific CD4+ T cells in the absence of a
virus-specific CD8+ T cell or B cell response. Enhanced
spread of FV infection in hosts with increased genetic sus-
ceptibility or during coinfection with lactate dehydroge-
nase-elevating virus (LDV) causes a proportional increase
in the number of FV-specific CD4+ T cells required to con-
trol FV-induced disease. Furthermore, ultimate failure of
FV/LDV coinfected hosts to control FV-induced disease is
accompanied by accelerated contraction of the FV-specific
CD4+ T cell response. Conversely, a further increased fre-
quency or constant supply of otherwise naïve FV-specific
CD4+ T cells is both necessary and sufficient to effectively
contain acute infection and prevent disease, even in the
presence of coinfection.
Conclusion
Thus, these results suggest that FV-specific CD4+ T cells
provide significant direct protection against acute FV
infection, the extent of which critically depends on the
ratio of FV-infected cells to FV-specific CD4+ T cells.
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